MA40318A - Procédés de transduction et de traitement de cellules - Google Patents
Procédés de transduction et de traitement de cellulesInfo
- Publication number
- MA40318A MA40318A MA040318A MA40318A MA40318A MA 40318 A MA40318 A MA 40318A MA 040318 A MA040318 A MA 040318A MA 40318 A MA40318 A MA 40318A MA 40318 A MA40318 A MA 40318A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- treatment
- chamber
- transduction
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 230000026683 transduction Effects 0.000 title abstract 3
- 238000010361 transduction Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B7/00—Elements of centrifuges
- B04B7/08—Rotary bowls
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
Abstract
L'invention porte sur des procédés, des systèmes et des kits pour le traitement cellulaire, par exemple pour un usage thérapeutique, par exemple pour une thérapie cellulaire adoptive. Les procédés fournis comprennent des procédés de transduction dans lesquels des cellules et des virus sont incubés dans des conditions qui entraînent la transduction des cellules avec un vecteur viral. L'incubation dans certains modes de réalisation est réalisée dans une cavité interne d'une chambre centrifuge généralement rigide, telle qu'une chambre cylindrique en plastique dur dont la cavité peut avoir un volume variable. Les procédés comprennent d'autres étapes de traitement, y compris celles réalisées dans une telle chambre, y compris le lavage, la sélection, l'isolement, la culture et la formulation. En particulier, la description concerne un procédé fournissant des avantages par rapport aux procédés de traitement disponibles, tels que les procédés disponibles pour un traitement à grande échelle. De tels avantages comprennent, par exemple, un coût réduit, une rationalisation, une efficacité accrue, une sécurité accrue et une reproductibilité accrue entre différents sujets et conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075801P | 2014-11-05 | 2014-11-05 | |
| US201562129023P | 2015-03-05 | 2015-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40318A true MA40318A (fr) | 2017-09-13 |
Family
ID=54754736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040318A MA40318A (fr) | 2014-11-05 | 2015-11-04 | Procédés de transduction et de traitement de cellules |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10428351B2 (fr) |
| EP (3) | EP3215601B1 (fr) |
| JP (4) | JP6740234B2 (fr) |
| KR (2) | KR102635942B1 (fr) |
| CN (2) | CN113736828A (fr) |
| AU (3) | AU2015343121B2 (fr) |
| BR (2) | BR112017009220B1 (fr) |
| CA (1) | CA2966538A1 (fr) |
| CY (1) | CY1123254T1 (fr) |
| DK (2) | DK3215601T3 (fr) |
| ES (2) | ES2805674T3 (fr) |
| FI (1) | FI3757206T3 (fr) |
| HR (1) | HRP20201128T1 (fr) |
| HU (1) | HUE050264T2 (fr) |
| IL (2) | IL252126B (fr) |
| LT (1) | LT3215601T (fr) |
| MA (1) | MA40318A (fr) |
| MX (3) | MX389108B (fr) |
| MY (1) | MY186199A (fr) |
| NZ (2) | NZ769598A (fr) |
| PH (1) | PH12017500824A1 (fr) |
| PL (2) | PL3215601T3 (fr) |
| PT (2) | PT3215601T (fr) |
| RS (1) | RS60685B1 (fr) |
| SG (2) | SG11201703656PA (fr) |
| SI (1) | SI3215601T1 (fr) |
| SM (1) | SMT202000397T1 (fr) |
| TW (3) | TWI787903B (fr) |
| WO (1) | WO2016073602A2 (fr) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| CA2946312A1 (fr) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Procedes d'isolement, de culture et de manipulation genetique de populations de cellules immunitaires pour une therapie adoptive |
| EP3805371A1 (fr) | 2014-05-15 | 2021-04-14 | National University of Singapore | Cellules tueuses naturelles modifiées et leurs utilisations |
| IL293714A (en) | 2014-10-20 | 2022-08-01 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| EP3215601B1 (fr) | 2014-11-05 | 2020-05-27 | Juno Therapeutics, Inc. | Procédés de transduction et de traitement de cellules |
| EP3233148B1 (fr) | 2014-12-19 | 2019-04-17 | Biosafe S.A. | Traitement séquentiel de fluides biologiques |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| AU2016341527B2 (en) | 2015-10-22 | 2023-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| US20170198303A1 (en) | 2015-12-04 | 2017-07-13 | Emory University | Methods, Devices and Systems for Enhanced Transduction Efficiency |
| CA3016871A1 (fr) * | 2016-03-07 | 2017-09-14 | Hitachi Chemical Advanced Therapeutics Solutions, LLC | Systeme ferme pour le marquage et la selection de cellules vivantes |
| WO2017161212A1 (fr) | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Procédés de conception adaptative d'un régime de traitement et traitements associés |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| KR20230107408A (ko) | 2016-07-29 | 2023-07-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | 항-cd19 항체에 대한 항-이디오타입 항체 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| WO2018049420A1 (fr) | 2016-09-12 | 2018-03-15 | Juno Therapeutics, Inc. | Ensembles de poches de bioréacteur de perfusion |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018102761A1 (fr) * | 2016-12-02 | 2018-06-07 | City Of Hope | Procédés de préparation et d'accroissement de lymphocytes t exprimant des récepteurs antigéniques chimériques et d'autres récepteurs |
| US20190350978A1 (en) * | 2016-12-05 | 2019-11-21 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| AU2018234640C9 (en) | 2017-03-14 | 2024-10-03 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
| CA3056439A1 (fr) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Recepteurs chimeriques de nkg2d tronques et leurs utilisations dans une immunotherapie de cellules tueuses naturelles |
| SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| EP3427052A4 (fr) * | 2017-03-27 | 2019-12-04 | Hitachi Chemical Advanced Therapeutics Solutions, LLC | Système fermé pour le marquage et la sélection de cellules vivantes |
| WO2018223101A1 (fr) * | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles de fabrication et procédés de traitement utilisant une thérapie cellulaire adoptive |
| US20230242654A1 (en) | 2017-07-29 | 2023-08-03 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
| IL315340A (en) * | 2017-09-01 | 2024-10-01 | Lonza Walkersville Inc | End-to-end cell therapy automation |
| EP3679370A1 (fr) | 2017-09-07 | 2020-07-15 | Juno Therapeutics, Inc. | Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire |
| SG11202003688PA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for generating therapeutic compositions of engineered cells |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| EP3704229B1 (fr) | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Procédé pour la production d'une composition de lymphocytes t |
| CN111556789A (zh) | 2017-11-10 | 2020-08-18 | 朱诺治疗学股份有限公司 | 封闭系统低温器皿 |
| KR102853341B1 (ko) | 2017-12-08 | 2025-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작된 ｔ 세포의 조성물을 제조하는 방법 |
| CA3084446A1 (fr) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Marqueurs phenotypiques pour therapie cellulaire et procedes associes |
| SG11202005228YA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Serum-free media formulation for culturing cells and methods of use thereof |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| KR20210059715A (ko) | 2018-08-09 | 2021-05-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | 통합된 핵산 평가 방법 |
| SG11202101204TA (en) * | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Processes for generating engineered cells and compositions thereof |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| EA202190693A1 (ru) | 2018-09-11 | 2021-07-27 | Джуно Терапьютикс, Инк. | Способы анализа масс-спектрометрии композиций модифицированных клеток |
| JP7396777B2 (ja) | 2018-09-28 | 2023-12-12 | オクタン バイオテック インコーポレーテッド | 磁気分離 |
| AU2019370705A1 (en) | 2018-10-31 | 2021-05-27 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| CA3117419A1 (fr) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methodes pour le traitement au moyen de recepteurs antigeniques chimeriques specifiques de l'antigene de maturation des lymphocytes b |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| EP3877054B1 (fr) | 2018-11-06 | 2023-11-01 | Juno Therapeutics, Inc. | Procédé de production de cellules t génétiquement modifiées |
| JP2022008735A (ja) * | 2018-11-06 | 2022-01-14 | テルモ株式会社 | 細胞製造システム、細胞製造方法、医療装置及び医療デバイス |
| KR20210104713A (ko) | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| WO2020113194A2 (fr) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Méthodes pour le traitement par thérapie cellulaire adoptive |
| EP3886894B1 (fr) | 2018-11-30 | 2024-03-13 | Juno Therapeutics, Inc. | Méthodes de dosage et de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| SG11202106053SA (en) * | 2018-12-07 | 2021-07-29 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for immunotherapy |
| IL284214B2 (en) | 2018-12-21 | 2025-03-01 | Octane Biotech Inc | Carousel for modular biologic production units |
| CA3123449A1 (fr) | 2018-12-21 | 2020-06-25 | Lonza Walkersville, Inc. | Production automatisee de vecteurs viraux |
| CA3128387A1 (fr) | 2019-02-08 | 2020-08-13 | Lonza Walkersville, Inc. | Methodes et dispositifs de concentration cellulaire destines a etre utilises dans des bioreacteurs automatises |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| JPWO2020196412A1 (fr) * | 2019-03-26 | 2020-10-01 | ||
| CA3139965A1 (fr) | 2019-06-07 | 2020-12-10 | Ivie AIFUWA | Culture de lymphocytes t automatisee |
| US12454681B2 (en) | 2019-06-10 | 2025-10-28 | I Peace, Inc. | Erythrocyte removal device, mononuclear cell collector, cell culture device, cell culture system, cell culture method, and mononuclear cell collection method |
| KR20220034782A (ko) | 2019-06-12 | 2022-03-18 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법 |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| CN114600172A (zh) | 2019-08-30 | 2022-06-07 | 朱诺治疗学股份有限公司 | 用于将细胞分类的机器学习方法 |
| MX2022004760A (es) | 2019-10-21 | 2022-07-21 | Flaskworks Llc | Sistemas y métodos para el cultivo de células. |
| IL292409A (en) | 2019-10-24 | 2022-06-01 | Octane Biotech Inc | A cell culture chamber with enhanced cell contact surfaces |
| AU2020377043A1 (en) | 2019-10-30 | 2022-06-02 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
| EP4055383A1 (fr) | 2019-11-05 | 2022-09-14 | Juno Therapeutics, Inc. | Procédés de détermination d'attributs de compositions de cellules t thérapeutiques |
| JP2023501443A (ja) | 2019-11-11 | 2023-01-18 | ロンザ ウォーカーズヴィル，インコーポレーテッド | 自動化された細胞処理のための品質制御方法 |
| JP2023504740A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法 |
| US20230192869A1 (en) | 2019-12-06 | 2023-06-22 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
| WO2021113770A1 (fr) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b |
| CN115003818A (zh) * | 2020-01-22 | 2022-09-02 | 科济生物医药（上海）有限公司 | 病毒载体转导细胞的方法 |
| MX2022009041A (es) | 2020-01-24 | 2022-10-07 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva. |
| EP4097218A1 (fr) | 2020-01-28 | 2022-12-07 | Juno Therapeutics, Inc. | Procédés pour la transduction de lymphocytes t |
| NZ790999A (en) * | 2020-02-06 | 2025-11-28 | Cutiss Ag | Cell isolation device and method |
| CN115768443A (zh) | 2020-02-12 | 2023-03-07 | 朱诺治疗学股份有限公司 | Cd19定向嵌合抗原受体t细胞组合物和方法及其用途 |
| BR112022015968A2 (pt) | 2020-02-12 | 2022-10-11 | Juno Therapeutics Inc | Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas |
| JP2023521052A (ja) * | 2020-04-03 | 2023-05-23 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | ウイルスの形質導入効率の向上 |
| WO2021207689A2 (fr) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Méthodes et utilisations associées à une thérapie cellulaire modifiée à l'aide d'un récepteur antigénique chimérique ciblant un antigène de maturation des lymphocytes b |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| KR20230022868A (ko) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 |
| WO2022029660A1 (fr) | 2020-08-05 | 2022-02-10 | Juno Therapeutics, Inc. | Anticorps anti-idiotypiques dirigés contre des domaines de liaison ciblés sur ror1 et compositions et procédés associés |
| WO2022133030A1 (fr) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2 |
| EP4294950A1 (fr) | 2021-02-20 | 2023-12-27 | Kite Pharma, Inc. | Marquers de gènes pour sélection de immunothérapies |
| AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| JP2024511418A (ja) | 2021-03-22 | 2024-03-13 | ジュノー セラピューティクス インコーポレイテッド | 治療用細胞組成物の効力を決定する方法 |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| EP4337227A2 (fr) | 2021-05-14 | 2024-03-20 | Kite Pharma, Inc. | Thérapie par lymphocytes t à récepteurs antigéniques chimériques |
| KR20240144434A (ko) | 2022-02-15 | 2024-10-02 | 카이트 파마 인코포레이티드 | 면역요법으로 인한 유해사례 예측 |
| AU2023272490A1 (en) | 2022-05-17 | 2024-12-12 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2023230548A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédé de prédiction d'une réponse à une thérapie par lymphocyte t |
| WO2023230581A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédés de fabrication de thérapies par lymphocytes t |
| KR20250029137A (ko) | 2022-06-22 | 2025-03-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법 |
| WO2024097992A2 (fr) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particules présentant des fusions de molécules d'adhésion |
| WO2024098038A2 (fr) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Construction polynucléotidique et vecteurs viraux et procédés associés |
| KR20250121074A (ko) | 2022-12-09 | 2025-08-11 | 주노 쎄러퓨티크스 인코퍼레이티드 | 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법 |
| CN120112624A (zh) * | 2023-01-03 | 2025-06-06 | 深圳华大生命科学研究院 | 分选流体系统及相关设备、流体分选方法及细胞分选方法 |
| TW202502363A (zh) | 2023-02-28 | 2025-01-16 | 美商奇諾治療有限公司 | 用於治療全身性自體免疫疾病之細胞療法 |
| WO2024220588A1 (fr) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Essai cytotoxique pour évaluer la puissance de compositions de cellules thérapeutiques |
| WO2024226858A1 (fr) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Procédés de fabrication de vecteurs viraux |
| WO2024238153A1 (fr) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Administration lentivirale de récepteurs antigéniques chimériques anti-cd20 |
| WO2024243365A2 (fr) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Marqueurs d'activation de lymphocytes t et procédé d'évaluation de l'activation de lymphocytes t |
| WO2025231174A1 (fr) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Fabrication de particules virales |
| WO2025235604A1 (fr) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Protéine de fusion destinée à être utilisée en tant qu'engageur de cellules immunitaires |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4163519A (en) | 1977-11-01 | 1979-08-07 | Union Carbide Corporation | Compensating rotor |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| SE454413B (sv) | 1986-09-12 | 1988-05-02 | Alfa Laval Separation Ab | Centrifugalseparator med en rotor, vari ett bojligt organ strecker sig ett stycke lengs rotorns omkrets |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| EP0452342B1 (fr) | 1988-12-28 | 1994-11-30 | MILTENYI, Stefan | Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| JP3150340B2 (ja) | 1990-11-13 | 2001-03-26 | イムネクス コーポレイション | 二機能選択可能融合遺伝子 |
| US5911983A (en) * | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| JPH09500783A (ja) | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 |
| US5437998A (en) * | 1993-09-09 | 1995-08-01 | Synthecon, Inc. | Gas permeable bioreactor and method of use |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| JP2000501614A (ja) | 1995-12-15 | 2000-02-15 | システミックス，インコーポレイテッド | 高形質導入効率を有するレトロウイルスベクター上清を得るための方法 |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (fr) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple |
| EP0912250B1 (fr) * | 1996-04-24 | 1999-11-03 | Claude Fell | Systeme de separation de cellules pour les liquides biologiques tels que le sang |
| DE69941836D1 (de) * | 1998-07-10 | 2010-02-04 | Univ Paris Curie | Verfahren zur Verabreichng von Nukleinsäuren in Zellen in vitro oder ex vivo |
| WO2000014257A1 (fr) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| HK1041454B (en) | 1998-12-24 | 2004-12-31 | 生物安全股份有限公司 | Blood separation system particularly for concentrating hematopoietic stem cells |
| US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| DE10136375A1 (de) | 2001-07-26 | 2003-02-13 | Cellgenix Technologie Transfer | Verfahren zur Anreicherung von Zellen |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7001513B2 (en) | 2003-08-06 | 2006-02-21 | Nuvue Technologies, Inc. | Automated processing of a biological component |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2345837T3 (es) | 2005-03-23 | 2010-10-04 | Biosafe S.A. | Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa. |
| JP5453629B2 (ja) | 2006-08-23 | 2014-03-26 | タカラバイオ株式会社 | 遠心用袋状容器を使用した遺伝子導入方法 |
| DK2856876T3 (en) | 2007-03-30 | 2018-04-03 | Memorial Sloan Kettering Cancer Center | Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes |
| EP2520643B8 (fr) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Systèmes de traitement d'échantillons et procédés |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| EP2310486B1 (fr) | 2008-07-16 | 2017-01-04 | kSep Systems, LLC | Procédés et systèmes de manipulation de particules à l'aide d'un lit fluidisé |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| CA2793648C (fr) | 2010-03-18 | 2017-06-06 | Syngen, Inc. | Systeme permettant de purifier certaines populations cellulaires dans le sang ou la moelle osseuse par depletion d'autres populations cellulaires |
| SE535275C2 (sv) | 2010-03-31 | 2012-06-12 | Alfa Laval Corp Ab | Centrifugalseparator och rotor |
| JP5793567B2 (ja) * | 2010-07-15 | 2015-10-14 | テルモ ビーシーティー、インコーポレーテッド | 生体液用の遠心分離装置において回転時間を最適化するための方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3179835A1 (fr) * | 2011-01-18 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions et procedes de traitement du cancer |
| NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| US9969966B2 (en) * | 2011-05-30 | 2018-05-15 | Atech Partners Limited | Bioreactor system for continuous cell cultivation |
| CN102329776B (zh) * | 2011-07-20 | 2013-02-27 | 华中农业大学 | 一种表达Nectin-1基因胞外区片段的PK-15细胞系及其构建方法 |
| KR101956751B1 (ko) * | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| EP2594632A1 (fr) * | 2011-11-18 | 2013-05-22 | Miltenyi Biotec GmbH | Procédé et dispositif de modification cellulaire |
| EP2814846B1 (fr) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
| WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
| CA2865033C (fr) * | 2012-02-23 | 2021-11-02 | Stage Cell Therapeutics Gmbh | Isolement chromatographique de cellules et d'autres materiaux biologiques complexes |
| PT2820138T (pt) | 2012-02-29 | 2020-12-24 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Transdução retroviral usando poloxameros |
| SG11201405185PA (en) | 2012-03-13 | 2014-10-30 | Emd Millipore Corp | Use of centrifugation-aided infection to increase virus titer |
| JP6251734B2 (ja) | 2012-05-03 | 2017-12-27 | フレッド ハッチンソン キャンサー リサーチ センター | 親和性増強型ｔ細胞受容体およびその作製方法 |
| HUE064187T2 (hu) * | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| EP2698208A1 (fr) | 2012-08-14 | 2014-02-19 | Fresenius Kabi Deutschland GmbH | Dispositif de centrifugation et procédé de fonctionnement dýun dispositif de centrifugation |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| US20160017048A1 (en) * | 2013-03-07 | 2016-01-21 | Baylor College Of Medicine | Targeting cd138 in cancer |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA3185368A1 (fr) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Generation efficace de lymphocytes t ciblant une tumeur derives de cellules souches pluripotentes |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| AU2014342020C1 (en) | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| CA2946312A1 (fr) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Procedes d'isolement, de culture et de manipulation genetique de populations de cellules immunitaires pour une therapie adoptive |
| CN106062185A (zh) | 2014-04-24 | 2016-10-26 | 美天旎生物技术有限公司 | 用于自动生成遗传修饰的t细胞的方法 |
| EP3215601B1 (fr) | 2014-11-05 | 2020-05-27 | Juno Therapeutics, Inc. | Procédés de transduction et de traitement de cellules |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
-
2015
- 2015-11-04 EP EP15802231.9A patent/EP3215601B1/fr active Active
- 2015-11-04 EP EP24168832.4A patent/EP4407036A3/fr active Pending
- 2015-11-04 BR BR112017009220-4A patent/BR112017009220B1/pt active IP Right Grant
- 2015-11-04 PL PL15802231T patent/PL3215601T3/pl unknown
- 2015-11-04 SM SM20200397T patent/SMT202000397T1/it unknown
- 2015-11-04 CN CN202111026157.8A patent/CN113736828A/zh active Pending
- 2015-11-04 MA MA040318A patent/MA40318A/fr unknown
- 2015-11-04 KR KR1020177015404A patent/KR102635942B1/ko active Active
- 2015-11-04 BR BR122020002722-3A patent/BR122020002722B1/pt not_active IP Right Cessation
- 2015-11-04 DK DK15802231.9T patent/DK3215601T3/da active
- 2015-11-04 PL PL20176047.7T patent/PL3757206T3/pl unknown
- 2015-11-04 FI FIEP20176047.7T patent/FI3757206T3/fi not_active Application Discontinuation
- 2015-11-04 CA CA2966538A patent/CA2966538A1/fr not_active Abandoned
- 2015-11-04 TW TW110125506A patent/TWI787903B/zh active
- 2015-11-04 HU HUE15802231A patent/HUE050264T2/hu unknown
- 2015-11-04 JP JP2017543300A patent/JP6740234B2/ja active Active
- 2015-11-04 SG SG11201703656PA patent/SG11201703656PA/en unknown
- 2015-11-04 TW TW111132488A patent/TW202315948A/zh unknown
- 2015-11-04 SI SI201531268T patent/SI3215601T1/sl unknown
- 2015-11-04 HR HRP20201128TT patent/HRP20201128T1/hr unknown
- 2015-11-04 RS RS20200887A patent/RS60685B1/sr unknown
- 2015-11-04 EP EP20176047.7A patent/EP3757206B1/fr active Active
- 2015-11-04 ES ES15802231T patent/ES2805674T3/es active Active
- 2015-11-04 LT LTEP15802231.9T patent/LT3215601T/lt unknown
- 2015-11-04 IL IL252126A patent/IL252126B/en unknown
- 2015-11-04 CN CN201580072404.4A patent/CN107109438B/zh active Active
- 2015-11-04 SG SG10202002324SA patent/SG10202002324SA/en unknown
- 2015-11-04 NZ NZ769598A patent/NZ769598A/en not_active IP Right Cessation
- 2015-11-04 DK DK20176047.7T patent/DK3757206T3/da active
- 2015-11-04 AU AU2015343121A patent/AU2015343121B2/en active Active
- 2015-11-04 KR KR1020247004412A patent/KR20240023204A/ko active Pending
- 2015-11-04 WO PCT/US2015/059030 patent/WO2016073602A2/fr not_active Ceased
- 2015-11-04 PT PT158022319T patent/PT3215601T/pt unknown
- 2015-11-04 TW TW104136385A patent/TWI735418B/zh active
- 2015-11-04 ES ES20176047T patent/ES2987570T3/es active Active
- 2015-11-04 NZ NZ769595A patent/NZ769595A/en not_active IP Right Cessation
- 2015-11-04 PT PT201760477T patent/PT3757206T/pt unknown
- 2015-11-04 US US14/932,660 patent/US10428351B2/en active Active
- 2015-11-04 IL IL292450A patent/IL292450A/en unknown
- 2015-11-04 MY MYPI2017000656A patent/MY186199A/en unknown
- 2015-11-04 MX MX2017005823A patent/MX389108B/es unknown
-
2017
- 2017-05-03 MX MX2021001334A patent/MX2021001334A/es unknown
- 2017-05-03 MX MX2022000159A patent/MX2022000159A/es unknown
- 2017-05-04 PH PH12017500824A patent/PH12017500824A1/en unknown
-
2019
- 2019-08-14 US US16/541,083 patent/US11802295B2/en active Active
-
2020
- 2020-07-22 JP JP2020124934A patent/JP7202332B2/ja active Active
- 2020-08-13 CY CY20201100763T patent/CY1123254T1/el unknown
- 2020-09-14 AU AU2020233623A patent/AU2020233623B2/en active Active
-
2022
- 2022-11-03 AU AU2022263539A patent/AU2022263539B2/en active Active
- 2022-12-23 JP JP2022206247A patent/JP2023024691A/ja active Pending
-
2023
- 2023-09-21 US US18/371,302 patent/US20240011051A1/en active Pending
-
2024
- 2024-08-19 JP JP2024137490A patent/JP2024159813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40318A (fr) | Procédés de transduction et de traitement de cellules | |
| WO2020123301A3 (fr) | Génération de réseaux spatiaux avec des gradients | |
| WO2017139505A3 (fr) | Procédés et compositions pour modifier un gène mutant de la dystrophine dans le génome d'une cellule | |
| EA202090740A1 (ru) | Перфузионный биореактор и связанные с ним способы применения | |
| EA201792441A2 (ru) | Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном | |
| MX2020009648A (es) | Muestreador de lecho fijo y metodos relacionados. | |
| BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
| BR112016024635A2 (pt) | meios de crescimento microbiológico e métodos de uso do mesmo | |
| MX383857B (es) | Métodos de cultivo de una célula de mamífero. | |
| Caro-Lopera et al. | Matrix-variate distribution theory under elliptical models-4: Joint distribution of latent roots of covariance matrix and the largest and smallest latent roots | |
| MX2022005663A (es) | Aparato y metodo de electroporacion. | |
| WO2016037036A3 (fr) | Procédés de détection d'oligomères bêta-amyloïdes | |
| Carman | Unit groups of representation rings and their ghost rings as inflation functors | |
| LANLAN | The Xujiahui Legacy | |
| RU2015147257A (ru) | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения | |
| EA201890720A1 (ru) | Лечение диабетической периферической нейропатии с применением плацентарных клеток | |
| Phuong et al. | MECHANICAL STRETCH ALTERS THE EXPRESSION PROFILE OF MECHANOSENSITIVE CHANNELS IN MOUSE RETINAL GANGLION CELLS VIA ACTIVATION OF TRPV4 | |
| Shumkov | REPLICATION TECHNOLOGY FEATURES OF PLASTIC PRODUCTS BY INJECTION OF TWO-COMPONENT COLD-POLYURETHANES SILICONE MOLD IN A VACUUM | |
| Maree | The Cellular Potts Model in the context of Cell Surface Mechanics | |
| Allred et al. | Susceptibility Of S49 Lymphoma Cell Membranes To Hydrolysis By Secretory Phospholipase A2 During Early Phase Of Apoptosis | |
| WO2020222703A3 (fr) | Dispositif d'ensemencement de cellules de dispersion | |
| Abbas Beh-Pajooh | The Role of RNA Interference during Reprogramming of Fibroblasts into Induced Pluripotent Stem Cells | |
| Vodret et al. | Application of a real-time PCR method for the detection of celery (Apium graveolens) in food [Conference poster]. | |
| WILLIAMS et al. | VISIONS: the art of science | |
| Herrmann | Turning failure into success: New perspectives for unsupervised NMR studies of proteins |